


## Managing CIED Requests from Terminal Patients


David Hayes, MD, Chief Medical Officer

 **BIOTRONIK**  
excellence for life

1

**My XX-year-old patient asked me to turn off his ICD, 'Tachy' therapies only, because he has end-stage cardiomyopathy. You would:**

1. Discuss in detail, document and abide by request
2. Request ethics consult
3. Request psych evaluation
4. Explain that ICD unlikely to alter course and best to leave as is

 **BIOTRONIK**  
excellence for life


2

**My XX-year-old ICD patient asked me to turn off his tachy and brady therapies because he has end-stage cardiomyopathy. He is pacemaker dependent. You would:**

1. Discuss in detail, document and abide by request
2. Agree to turn off tachy therapies but not pacing therapies
3. Request ethics consult
4. Explain that ICD unlikely to alter course and best to leave as is



3



4

## Ethical Aspects Of Deactivating Implanted Cardiac Devices

Increased prevalence of devices in dying patients

- End-of-life (EOL) discussions with cardiologists are not done routinely
- Patients and families fear devices prolong the dying process
- Patients with ICDs may experience uncomfortable therapies




5

## Ethical Aspects Of Deactivating Implanted Cardiac Devices

- Is device deactivation ethical? Is it legal?
- Is device deactivation more like withdrawing other life sustaining therapies (LSTs), or more like physician assisted suicide (PAS) and euthanasia?
- Under what conditions (eg, code status) should deactivation be done?
- Who should carry out deactivation?



6



Europace (2017), 8, 1-8  
doi:10.1093/europace/eu019

REVIEW

## Ethics and the cardiac pacemaker: more than just end-of-life issues

**Katrina Hutchison<sup>1\*</sup>, and Robert Sparrow<sup>2</sup>**

<sup>1</sup>Philosophy Program, ANU, Centre of Excellence for Environmentally Science, Monash University, Wellington Road, Melbourne, VIC 3000, Australia and <sup>2</sup>Philosophy Program, Centre for Human Bioethics, ANU, Centre of Excellence for Environmentally Science, Monash University, Wellington Road, Melbourne, VIC 3000, Australia.

Received 20 June 2016; editorial decision 17 January 2017; accepted 30 March 2017

# Ethics and the Cardiac Pacemaker: More than just End-of-Life Issues

Katrina Hutchison and Robert Sparrow


issues. In this paper, we review the ethical issues posed by pacemakers, and advocate for clinicians to be attentive to all these issues in their practice. In addition to the ethical challenges associated with pacemaker deactivation in end of life care, we analyse five other issues that have been relatively neglected in the literature: potential conflicts of interest, especially those associated with industry employed allied professionals (EAPs); unanticipated impacts of commercial competition and the continuing cycle of device improvement; risks associated with remotely accessible software; equity in access to healthcare; and questions about reuse of explanted pacemakers in low and middle income countries. Some of these are most urgent for regulators and manufacturers of pacemakers. However, clinicians should be aware of these issues, and can offer a unique perspective on how to address them. To facilitate better engagement with these issues by cardiologists and other members of the medical profession,

on end of life care and withdrawal of treatment.<sup>1-8</sup> Pacemakers are a difficult case in this context. Implanted devices are more likely to be perceived by both patients and health professionals as part of patients' bodies, and thus may not be straightforwardly regarded as the sort of 'treatment' that can be withdrawn.<sup>9,10</sup> This is further complicated when patients are pacemaker dependent. In these patients, deactivation leads quickly to increased suffering and likely death. Studies with health professionals responsible for device deactivation in end-of-life settings suggest that they are much more reluctant to deactivate a pacemaker in a pacemaker-dependent patient than a device such as an implanted cardioverter defibrillator (ICD) that only intervenes intermittently and might increase suffering by giving shocks to a dying patient.<sup>11</sup>

There is also controversy about who should carry out the deactivation. In some jurisdictions, EAPs are expected to deactivate cardiac

\* Corresponding author. Tel: +61 3 9905 5379. E-mail address: [katrina.hutchison@monash.edu](mailto:katrina.hutchison@monash.edu).  
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: [journal.permissions@oup.com](mailto:journal.permissions@oup.com).

Downloaded from <https://academic.oup.com/europace/advance-article-abstract/doi/10.1093/europace/eu019/13101578> by Mark Clavin, Division of Biostatistics user on 17 March 2017



**BIOTRONIK**  
excellence for life

7

## Withholding and Withdrawing Life-Sustaining Treatments (LST)

- Many types of LSTs: dialysis, ventilation, artificial nutrition, etc.
- In the US, withholding and withdrawing LSTs ethical and legal:
  - Respect for patient autonomy
  - Famous legal cases; not a "right to die," but a right to be left alone (liberty interest)
- There is no ethical or legal distinction between withholding and withdrawing

8

8

## Vacco v. Quill: U.S. Supreme Court, 1997

“The distinction comports with fundamental legal principles of causation and intent. First, when a patient refuses life-sustaining medical treatment, he dies from an underlying fatal disease or pathology; but if a patient ingests lethal medication prescribed by a physician, he is killed by that medication...[In Cruzan] our assumption of a right to refuse treatment was grounded not...on the proposition that patients have a...right to hasten death, but on well established, traditional rights to bodily integrity and freedom from unwanted touching.”

## Withholding and Withdrawing Life-Sustaining Treatments

- Dying patients [or families] frequently make such requests
- Honoring these requests is not the same as physician-assisted suicide (PAS) or euthanasia
- The clinician is obligated to ensure the patient [surrogate/family] understands the consequences and alternatives to the request

## Withholding and Withdrawing Life-Sustaining Treatments

	<b>Withhold LST</b>	<b>Withdraw LST</b>	<b>Terminal analgesia</b>	<b>Physician-assisted suicide</b>	<b>Euthanasia</b>
Cause of death	Underlying disease	Underlying disease	Underlying disease <sup>†</sup>	Intervention prescribed by physician and used by patient	Intervention used by physician
Intent/goal of intervention	Avoid burdensome intervention				Termination of the patient's life
Legal?	Yes <sup>†</sup>	Yes <sup>†</sup>	Yes	Some states*	No

<sup>†</sup>Terminal analgesia may hasten death ("double effect")

<sup>†</sup>Legal in all states but some limit the power of surrogates regarding LSTs

\*Legal in California, Colorado, District of Columbia, Hawaii, Montana, Maine, New Jersey, New Mexico, Oregon, Vermont, and Washington.



11

## Caregivers Cannot Be Forced To Violate Their Moral/Religious Convictions

- You cannot compel a clinician/caregiver to perform a medical procedure he or she views as morally unacceptable
- A process must be in place whereby deactivation could be done once all appropriate steps are completed



12

## Ethical Aspects Of Deactivating Implanted Cardiac Devices

Is deactivation of a pacemaker the same as deactivating an ICD or CRT?

- Perform different functions
- Deactivation may have different outcomes if the patient is pacemaker dependent
- Some argue devices do not prolong the dying process
- Withholding and withdrawing treatments are viewed as the same legally and ethically

13

### HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy

This document was developed in collaboration and endorsed by the American College of Cardiology (ACC), the American Geriatrics Society (AGS), the American Academy of Hospice and Palliative Medicine (AAHPM); the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), and the Hospice and Palliative Nurses Association (HPNA).

Rachel Lampert, MD, FHRS,\* David L. Hayes, MD, FHRS,<sup>1</sup> George J. Annas, JD, MPH,<sup>1</sup> Margaret A. Farley, PhD,<sup>2</sup> Nathan E. Goldstein, MD,<sup>3</sup> Robert M. Hamilton, MD,\*\* G. Neal Kay, MD, FHRS,<sup>1†</sup> Daniel B. Kramer, MD,<sup>1‡</sup> Paul S. Mueller, MD, MPH,<sup>1</sup> Luigi Padeletti, MD,<sup>4¶</sup> Leo Pozuelo, MD,<sup>1§</sup> Mark H. Schoenfeld, MD, FHRS,<sup>5</sup> Panos E. Vardas, MD, PhD,<sup>6\*\*</sup> Debra L. Wiegand, PhD, RN,<sup>1||</sup> Richard Zellner, JD, MA<sup>1||</sup>

\*Yale University, School of Medicine, New Haven, CT; <sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Boston University, School of Public Health, Boston, MA; <sup>3</sup>Yale University Divinity School, New Haven, CT; <sup>4</sup>Mount Sinai School of Medicine New York, NY and the James J. Peters VA Medical Center, Bronx, NY; <sup>5</sup>The Hospital for Sick Children, Toronto, Canada; <sup>6</sup>The University of Alabama at Birmingham, Birmingham, AL; <sup>†</sup>Beth Israel Deaconess Medical Center, Boston, MA; <sup>‡</sup>University of Florence, Institute of Cardiology, Florence, Italy; <sup>¶</sup>Cleveland Clinic, Cleveland, OH; <sup>\*\*</sup>Hershey Medical Center, Hershey, PA; <sup>§</sup>University of Maryland, School of Nursing, Baltimore, MD; <sup>||</sup>Patient representative; Adjunct lecturer at Case Western Reserve University, Bioethics Department, Cleveland, OH.

### HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy

Rachel Lampert, MD, FHRS, David L. Hayes, MD, FHRS, George J. Annas, JD, MPH, Margaret A. Farley, PhD, Nathan E. Goldstein, MD, Robert M. Hamilton, MD, G. Neal Kay, MD, FHRS, Daniel B. Kramer, MD, Paul S. Mueller, MD, MPH, Luigi Padeletti, MD, Leo Pozuelo, MD, Mark H. Schoenfeld, MD, FHRS, Panos E. Vardas, MD, PhD, Debra L. Wiegand, PhD, RN, Richard Zellner, JD, MA


American Academy of Hospice and Palliative Medicine (Nathan E. Goldstein), American Heart Association and the Hospice and Palliative Nurses Association (Debra L. Wiegand), European Heart Rhythm Association (Luigi Padeletti and Panos E. Vardas). Endorsed by the Heart Rhythm Society on May 3, 2010.

understanding of device deactivation varies<sup>1,2</sup> and studies show that many physicians report uneasiness with conversations addressing device management as patients near the end of their lives.<sup>3</sup> Few patients or families discuss the

1547-5271/\$ - see front matter © 2010 Published by Elsevier Inc. on behalf of Heart Rhythm Society.

doi:10.1016/j.hrthm.2010.04.033

14


Europe (2019) 12, 1485–1489  
doi:10.1093/eurheartj/ehz075
**CONSENSUS STATEMENT**

### EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy

**Luigi Padeletti<sup>1\*</sup>, David O. Arnar<sup>2</sup>, Lorenzo Boncinelli<sup>3</sup>, Johannes Brachman<sup>4</sup>, John A. Camm<sup>5</sup>, Jean Claude Daubert<sup>6</sup>, Sarah Kassam<sup>6</sup>, Luc Deliens<sup>7</sup>, Michael Glikson<sup>8</sup>, David Hayes<sup>9</sup>, Carsten Israel<sup>10</sup>, Rachel Lampert<sup>11</sup>, Trudie Lobban<sup>12</sup>, Pekka Raatikainen<sup>13</sup>, Gil Siegal<sup>14</sup>, and Panos Vardas<sup>15</sup>**


<sup>1</sup>Department of Pain Management, <sup>2</sup>Brigham Brigham, <sup>3</sup>Università Cattolica, <sup>4</sup>Fritz-Hum, <sup>5</sup>Imperial College, <sup>6</sup>Université de Liège, <sup>7</sup>Université de Liège, <sup>8</sup>University of Groningen, <sup>9</sup>Department of Heart and Vessels, University of Florence, Florence, Italy, <sup>10</sup>Division of Cardiology, Department of Internal Medicine, Lundagård University Hospital, Malmö, Sweden, <sup>11</sup>Department of Geriatric Cardiology and Medicine, University of Florence, Florence, Italy, <sup>12</sup>St. Jan, Ghent, Belgium, <sup>13</sup>Department of Cardiac and Vascular Sciences, St. George's University of London, London, UK, <sup>14</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>15</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>16</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>17</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>18</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>19</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>20</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>21</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>22</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>23</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>24</sup>Department of Cardiology, Hammersmith Hospital, London, UK, <sup>25</sup>Department of Cardiology, Hammersmith Hospital, London, UK

**EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy**

Luigi Padeletti, David O. Arnar, Lorenzo Boncinelli, Johannes Brachman, John A. Camm, Jean Claude Daubert, Sarah Kassam, Luc Deliens, Michael Glikson, David Hayes, Carsten Israel, Rachel Lampert, Trudie Lobban, Pekka Raatikainen, Gil Siegal, and Panos Vardas

We appreciate that implantable cardioverter-defibrillator (ICD) is the treatment of choice for patients who are at risk of sudden cardiac death due to ventricular arrhythmias. Randomized prospective trials have established that the ICD is superior to antiarrhythmic drug therapy in both primary and secondary prevention. Economic data (http://www.economic.org) indicate that in 2008, ICD use, alone or associated with cardiac resynchronization therapy (CRT), continued to grow. Chronic noncardiac disease. Terminal illness patients are more likely to develop conditions such as hypoxia, apnea, pain, heart failure, and electrolyte disturbances predisposing them to arrhythmias and thus increasing the frequency of shock therapy. Shocks can be physically painful and psychologically stressful, without prolonging a life of acceptable quality, a result which is inconsistent with comfort care goals. Therefore, it is appropriate to consider

\*Corresponding author. Tel: +39 055447620; fax: +39 055447626; Email: lpadeletti@uniflo.it  
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2019. For permissions please email: journals.permissions@oxfordjournals.org



15

Received: 13 July 2018
Revised: 13 December 2018
Accepted: 13 February 2019

DOI: 10.1111/pace.13641

**PATIENT EDUCATION**

# PACE



**WILEY**

## Planning ahead: End-of-life decisions for patients with defibrillators

Casey E. Cavanagh PhD<sup>1,2</sup>  | Lindsey Rosman PhD<sup>1,2</sup>  | Rachel Lampert MD<sup>1</sup> | Philip W. Chui MD<sup>2,3</sup> | Mary L. Johnston APRN<sup>4</sup> | Matthew M. Burg PhD<sup>1,5</sup>

<sup>1</sup>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut  
<sup>2</sup>Pain, Research, Informatics, Multimorbidities, and Education (PRIME) Center, VA Connecticut Healthcare System, West Haven, Connecticut  
<sup>3</sup>Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut  
<sup>4</sup>VA Connecticut Healthcare System, West Haven, Connecticut  
<sup>5</sup>Department of Anesthesiology, Yale School of Medicine, New Haven, Connecticut



16



## Written Documentation Required

1. Confirmation that the patient or surrogate has requested device deactivation
2. Capacity of the patient to make the decision, or identification of the appropriate surrogate
3. Confirmation that alternative therapies have been discussed if relevant
4. Confirmation that consequences of deactivation have been discussed
5. The specific device therapies to be deactivated
6. Notification of family, if appropriate



17

## My XX-year-old patient just asked me to turn off his ICD because.....

- Legally the answer would be the same for all scenarios, i.e. the patient owns the decision
- Practically and clinically, different approaches may be appropriate, e.g. if the patient just lost his spouse, assess psychiatric status and treat if needed
- The “moral compass” of the caregiver involved should be respected but not dictate care
- Many caregivers would perceive the pacemaker dependency issue differently, even if legally there is no distinction

© 2024 BIOTRONIK, Inc. All rights reserved. PPT\_EDU\_024\_CIED Managing End of Life CIED\_External 5\_29\_2024



18